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Abstract
Human studies demonstrate that sleep impairment is a concurrent comorbidity of autism spectrum disorders (ASD),
but its etiology remains largely uncertain. One of the prominent theories of ASD suggests that an imbalance in
synaptic excitation/inhibition may contribute to various aspects of ASD, including sleep impairments. Following the
identification of Nlgn3R451C mutation in patients with ASD, its effects on synaptic transmission and social behaviours
have been examined extensively in the mouse model. However, the contributory role of this mutation to sleep
impairments in ASD remains unknown. In this study, we showed that Nlgn3R451C knock-in mice, an established
genetic model for ASD, exhibited normal duration and distribution of sleep/wake states but significantly altered
electroencephalography (EEG) power spectral profiles for wake and sleep.
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Introduction
Autism spectrum disorders (ASD) are a class of perva-
sive neurodevelopmental conditions, affecting 1 in 110
children [1, 2]. ASD are diagnosed based on impaired
social interaction, impaired communication, and re-
stricted behavioural stereotypies. In addition, sleep im-
pairment is reported as one of the most concurrent
symptoms in this population [3, 4]; 40–80% of children
with ASD are reported to have some sleep abnormalities
[3–11]. Currently, sleep abnormalities in patients with
ASD are largely undertreated as other symptoms take
precedence [3]. However, studies show that core symp-
toms of ASD as well as behavioural measures are wors-
ened by poor sleep quality [3], highlighting the
importance to understand and treat sleep abnormalities
in ASD. For example, the severity of social and commu-
nication deficits are exacerbated following sleep
deprivation [3, 12, 13]. In addition, sleep impairments
were also linked to increased aggression, irritability, hyper-
activity, and affective problems, that may further impair
daytime functioning of patients with ASD [3, 13–16]. Des-
pite the pervasiveness of sleep impairment in the ASD
population, its neurochemical underpinnings remain
unclear.
ASD are usually diagnosed between the ages of 2 to 4,
a developmental period with extensive activity-
dependent neuronal remodelling, but their symptoms per-
sist throughout adulthood [2, 17]. A prominent neuro-
chemical notion for ASD etiology is the excitation/
inhibition (E/I) imbalance theory which suggests that al-
tered neuronal network excitability may underline ASD [2,
18, 19]. For example, while an upregulation of α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) re-
ceptors, the principal mediator of fast excitatory synaptic
transmission, was found in post-mortem brain samples of
patients with ASD, a concomitant downregulation of the
inhibitory γ-aminobutyric acid (GABA) receptors was
found [2]. Furthermore, abnormal cortical and subcortical
excitability was also proposed to be a critical contributor to
sleep impairment in ASD [4].
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Neuroligins (Nlgns), a family of postsynaptic cell ad-
hesion proteins, are crucial for neuronal E/I balance
through their regulation of GABAergic and glutamater-
gic synaptic strength [18, 20–23]. To date, 5 Nlgn family
members have been identified in humans, including
Nlgn 1-3, which have close homologs in mice [24, 25].
Importantly, a missense mutation in Nlgn3 (Nlgn3R451C),
which results in its reduced synaptic expression due
to increased retention in the endoplasmic reticulum
[24, 26], is linked with ASD in humans [24, 25, 27]
as well as impaired social interaction and vocal com-
munication in rodent models [24, 28–30]. Although
Nlgn3 is ubiquitously expressed in the brain, its func-
tion in synaptic transmission appears to be region-
specific, affecting the somatosensory cortex and the
hippocampus differently [24, 30]. Recently, a number
of studies have looked at the role of neuroligins in
sleep. In one study, Nlgn1 knockout mice were
unable to maintain wakefulness and spent more time
in NREM sleep [31] while drosophila deficient in
neuroligin 4 exhibited impaired night sleep in another
study [32]. To date, although numerous studies have dem-
onstrated that Nlgn3R451C mutation is linked to impaired
social interaction and memory, whether it also contributes
to sleep impairment is unknown. In this study, we
employed electroencephalography (EEG)-electromyography
(EMG) recordings to evaluate sleep properties in
Nlgn3R451C knock-in (KI) mice. We demonstrated altered






Fig. 1 Representative traces of EEG-EMG recordings in a WT mouse. For each mouse, continuous recordings for 48 h were done (top 2 channels:
EEG; bottom 2 channels: EMG). The top EEG channel is from left frontal electrode recording with reference to cerebellum. The second EEG
channel is from right parietal electrode recording with reference to cerebellum. a Wake EEG is predominated by oscillations greater or equal to
theta oscillations (≥5 Hz) with varying amplitude and is irregular in comparison to NREM and REM sleep. b, c NREM sleep is predominated by
either high amplitude delta waves (<4 Hz) or mixed high amplitude theta/delta waves in the EEG channels and low muscle activity. The mixed
high amplitude theta/delta waves in our mice often occur before transitioning into REM sleep. d REM sleep is characterized by regular low
amplitude theta waves (≥7 Hz) in the EEG channels associated with muscle atonia. Every gridline marks 1 s in duration. The amplitude scale for
EEG is 100 μV and the amplitude scale for EMG is 300 μV
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Methods
Animals, housing conditions, and genotyping
Adult Nlgn3R451C mice obtained from the Jackson
Laboratory were housed and bred under a 12 h light-
12 h dark cycle (light on 6:40 am, light off 6:40 pm) with
constant ambient temperature. Food and water were
provided ad libitum. All animal protocols were approved
by the Animal Lab Services ethics committee of the
Hospital for Sick Children. To determine the genotype
(wild type or knock-in) of the mice, the DNA fragments
were amplified using polymerase chain reaction (PCR)
with primers 5’- TGTACCAGGAATGGGAAGCAG-3’
and 5’- GGTCAGAGCTGTCATTGTCAC-3’ using the
conditions recommended by the Jackson Laboratory.
Stereotaxic surgery
Adult male mice [WT = 19.1 ± 1.0 (SEM) weeks, 33.4
± 0.7 g, n = 7; Nlgn3R451C KI = 19.3 ± 1.1 (SEM) weeks,
30.6 ± 0.6 g, n = 7] were used for surgery. Three cor-
tical electrodes for EEG recordings and two insulated
stainless steel wires (0.011 mm diameter, Cooner
Wire, Chatsworth, CA, USA) for EMG recordings
were soldered to a multi-channel connector (Digi-Key
Electronics, Thief River Falls, MN, USA) prior to
implantation. Animals were anesthetized using keta-
mine (100–150 mg/kg as needed, intraperitoneal, i.p.)
and xylazine (7–10 mg/kg as needed, i.p.) prior to
surgery. The three electrodes were inserted through
holes made in the skull and placed against the dura,
over the cerebellum, left frontal lobe (1.7 mm lateral
to midline and 1.5 mm anterior to bregma), and right
parietal lobe (1.7 mm lateral to midline and 1.0 anter-
ior to lambda). In addition, 2 stainless steel wires
were sutured into the neck muscles. Dental acrylic
(Lang Dental Manufacturing Co., Inc., Wheeling, IL,
USA) was used to secure the multi-channel connector
to the skull. After surgery, ketoprofen (5 mg/kg, sub-
cutaneous, s.c.) was administered for post-operative
pain control and 1 ml 0.9% saline (s.c.) was administered
for fluid loading.
Fig. 2 Total sleep-wake time in Nlgn3R451C mutant mice. Proportion of total time spent in each vigilance state during the 12-h light and 12-h dark
periods in WT (n = 7) and Nlgn3R451C mice (KI, n = 7). Student t-test was used for this set of analysis. Both WT and Nlgn3R451C mice spent more
time in NREM and REM sleep during the light period than they did during the dark period. Nlgn3R451C mice did not significantly alter the time
that the mice spent in wake (a), NREM sleep (c), and REM sleep (e) during light period (all p >0.15. Nlgn3R451C mice did not significantly alter the
time that the mice spent in wake (b), NREM sleep (d), and REM (f) sleep during dark period (all p >0.28)
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Experimental protocol and data acquisition
All mice were recovered for at least 8 days in their
home cage and were habituated individually for
another 3 days in the recording chamber prior to the
48 h EEG-EMG recording. Seven pairs of age-
matched Nlgn3R451C and their wildtype (WT) litter-
mate were used for EEG-EMG recordings. The light-
dark cycle during recording was kept consistent with
the housing room condition. EEG and EMG signals
were recorded, amplified, and filtered with HFF at
1 Hz and LFF at 90 Hz using Grasslab (Natus Neurology
Incorporated – Grass Products, Warwick, RI, USA) and
sampled at 512 Hz.
Sleep wake states determination
The 48 h recordings were visually scored for sleep-
wake states by independent investigators who were
blind to the genotype of the mice. Sleep-wake states
were identified by inspecting both EEG and EMG sig-
nals using 4-s epochs, and classified into wakefulness,
NREM sleep, and REM sleep, as previously described
[33]. Sample EEG-EMG traces of each sleep-wake
state are shown in Fig. 1.
EEG spectral analysis
The two EEG channels were subtracted to obtain a
single EEG signal for Fast Fourier Transformation
(FFT) using MatLab (MathWorks, Natick, MA, USA).
These signals were further filtered to reduce noise
prior to FFT and only frequency bands below 56 Hz
were subjected to FFT. To achieve these, the filters
were set as HFF = 0.55 Hz, band stop = 0.45 Hz, band
stop = 60 Hz. Total EEG power (μV2) between 1 and
56 Hz for each 4 s epoch were obtained using
MATLAB. To normalize the data, EEG power (μV2)
for each frequency bin within each epoch was calcu-
lated as a percentage of the average of the total EEG
powers (1–56 Hz) of all epochs.
Statistical analysis
The EEG-EMG signals of each mouse were recorded
for 48 h. The data from the 2 days were averaged.
As noise in our recordings was characterized by very
high amplitude oscillations, we removed all epochs
with any frequency band that has a power of greater
than 300% after normalization (regardless of fre-
quency bands and sleep state, but most of these
occur during wake states). The data were then re-
normalized after the removal of these epochs. Once
again, epochs with any 1 Hz frequency bin that has
a normalized power > 300% were removed. This
accounted for 2.1% of WT data and 2.2% of KI data.
This was done to reduce the effect of extremely high
amplitudes outlier oscillations on the overall data by
reducing skewing effect. All the averaged data were
stated as mean ± SEM and statistically evaluated by
Student’s t-test for comparisons of two groups, or
ANOVA (one-way, two-way or repeated measures
wherever appropriate) for comparisons of more than
two groups followed by post-hoc Bonferroni t-tests.
Fig. 3 Time-of-day profile of vigilance states in WT and Nlgn3R451C
mutant mice. The distribution profile of each vigilance state across
the entire recording. Nlgn3R451C mutant mice exhibited a trend of
less NREM sleep than WT (p = 0.051) (b), while the two groups did
not differ from each other for wakefulness (a) and REM sleep (c)
(genotype: both > 0.11)
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Fig. 4 Sleep-wake episodes in Nlgn3R451C mutant mice. Total number of episodes and the mean episode duration for each vigilance state were compared
between WT (n= 7) and Nlgn3R451C mice (KI, n= 7) using student t-test. Episode number of each state and their mean episode duration were separately
assessed in the light (a, c, e, g, i, and k) or dark phase (b, d, f, h, j, and l). Nlgn3R451C mutation did not result in significant alteration in the number of
episodes (all p>0.45) nor the mean episode duration (all p>0.13) of wake (a to d), NREM (e to h), and REM sleep (i to l) in the light period or the dark period
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Results
Nlgn3R451C mutant mice exhibit normal time-of-day
distribution of sleep-wake states across time-of-day
and sleep fragmentation
We first analyzed if the proportion of time spent in each
state differed between the first day and second day of
recordings. As day 1 and day 2 did not differ signifi-
cantly for any of the state (all p >0.098), the two days’
data were averaged for subsequent analysis. As patients
with ASD often have shortened sleep duration, longer
waking duration during the night, and altered circadian
rhythm for sleep [3, 10, 14, 34], we analyzed the propor-
tion of time that the mice spent in each vigilance state
and their distribution during the light (ZT1-12 h) and
dark (ZT13-24 h) periods. During both the light and
dark periods, the Nlgn3R451C mutant mice did not differ
significantly from their WT littermates in the proportion
of time that they spent in wakefulness, NREM sleep, and
REM sleep (all p >0.14) (Fig. 2). To determine the effect
of Nlgn3R451C mutation on the distribution of vigilance
states across the time-of-day, we analyzed the proportion
of time spent during each hour over the 24 h recording
period, and found no significant difference between
genotypes for all three states (genotype: all p >0.05)
(Fig. 3). As patients with ASD are often reported to have
more fragmented sleep or more frequent awakenings
after sleep onset than non-ASD subjects [3, 34], we also
examined if Nlgn3R451C mutant mice had alterations in
the number of episodes and the duration of each individ-
ual sleep-wake episode. As shown in Fig. 4, there were no
significant differences between Nlgn3R451C mutant mice
and WT controls in the number (all p >0.45) or the
duration of sleep/wake episodes (all p >0.13) (Fig. 4).
Taken together, these results suggest that Nlgn3R451C
mutation does not significantly affect the overall sleep/
wake duration or contribute to fragmentation of sleep.
Nlgn3R451C mutant mice exhibit altered power spectral
profiles for wakefulness, NREM, and REM sleep
In order to examine the role of Nlgn3 in sleep quality,
power spectrum of each state was compared between
genotypes. Firstly, the mean spectral powers of 1 Hz
Fig. 5 Power spectral profiles of WT and Nlgn3R451C mutant mice.
The power of the individual frequency band (1 Hz bins) was
normalized by expressing it as % of the average of total power
(1-56 Hz for all epochs). Repeated measure two-way ANOVA using
“genotype” and “frequency” as factors revealed significant genotype-
frequency interaction for NREM sleep (F= 2.856, p<0.001). The NREM (B)
spectral profile of Nlgn3R451C (KI) mice differed significantly between
2-8 Hz from WT mice (WT, n= 7; KI, n= 7; all p<0.05). More specifically,
Nlgn3R451C mice had reduced powers between 2-8 Hz during NREM
sleep (b) in comparison to WT mice. No significant genotype
effect or genotype-frequency interactions were found for wake
(a) and REM (c) states
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bands in each vigilance state were normalized (to the
average of the total power of all 1 Hz bins from 1 to
56 Hz across all epochs) and expressed as percentage of
the total power. Significant genotype-frequency inter-
action was found for NREM state (F = 2.856, p <0.001)
(Fig. 5). More specifically, post-hoc Bonferroni test
showed significantly reduced EEG power between 2-
8 Hz in Nlgn3R451C mice (p <0.05) (Fig. 5). On the other
hand, no significant “genotype” or “genotype-frequency”
interactions were found for wake or REM sleep (both
p >0.11) (Fig. 5). In addition, the normalized powers of
delta (1–4 Hz), theta (5–8 Hz), alpha (9–12 Hz), sigma
(13–15 Hz), and beta (15–30 Hz) frequency bands were
examined in each sleep/wake state over time as these are
indicators of cortical arousal and sleep quality [35–44].
These bands were normalized to the total power of
1–56 Hz as described above. These analyses revealed
significantly altered wake/sleep EEG spectral profile in
Nlgn3R451C mutant mice. Specifically, the EEG sigma
(F = 7.363, p <0.01) and beta (F = 9.024, p <0.01) pow-
ers were all significantly higher in Nlgn3R451C mutant
mice during wakefulness in comparison to WT mice
(Table. 1, Fig. 6). Delta power during NREM sleep,
which is an indicator of sleep depth [36], was reduced
in Nlgn3R451C mutants (F = 20.981, p <0.001) (Table 1,
Fig. 6). Theta (F = 30.622, p <0.001) and alpha (F = 6.162,
p <0.05) powers during NREM sleep were also reduced in
Nlgn3R451C mice (Table 1, Fig. 6). During REM sleep,
while alpha power (F = 12.069, p <0.001) was reduced in
Nlgn3R451C mice, beta power was increased in Nlgn3R451C
mice (F = 4.829, p < 0.05) (Table 1, Fig. 6). During wake-
fulness, time had a significant main effect on beta power
(F = 2.226, p <0.05) (Table 1). During NREM sleep, time
had a significant main effect on delta power (F = 2.612, p
< 0.05) (Table 1). Frequency bands with no main genotype
effect (p >0.05) are not included in Fig. 6. In another set of
analysis for time effect, we normalized the data of each
frequency band by expressing it as a % of mean 24 h activ-
ity of each mouse for the targeted band within each
arousal state. These analysis revealed significant time
effect for all frequency bands (i.e. delta, theta, alpha,
sigma, and beta; all p <0.001) in both genotypes. More
specifically, EEG power for all of the stated bands were
higher during the dark period for wakefulness, whereas
EEG power for all of these bands were higher during
the light period for NREM and REM sleep. Further-
more, we found no significant genotype-time inter-
action (all p >0.3), which is consistent with what we
Table 1 Summary statistics for wake, NREM sleep, and REM sleep
Df Delta Theta Alpha Sigma Beta
Wake
Gen 1 F = 2.317 F = 2.916 F = 1.224 F = 7.363 F = 9.024
p = 0.131 p = 0.091 p = 0.271 p = 0.008** p = 0.003**
Time 7 F =1.601 F =0.327 F =2.717 F = 1.597 F = 2.226
p =0.144 p =0.940 p =0.013* p = 0.146 p = 0.039*
Inter 7 F = 0.470 F = 0.092 F = 0.061 F = 0.136 F = 0.046
p = 0.854 p =0.999 p = 1.000 p = 0.995 p = 1.000
NREM
Gen 1 F = 20.981 F = 30.622 F = 6.162 F = 0.140 F = 0.457
p <0.001*** p <0.001*** p = 0.015* p = 0.709 p = 0.501
Time 7 F = 2.612 F = 0.623 F = 0.127 F = 0.221 F = 0.430
p = 0.016* p = 0.735 p = 0.996 p = 0.980 p = 0.881
Inter 7 F = 0.184 F = 0.120 F = 0.021 F = 0.023 F = 0.027
p = 0.988 p = 0.997 p = 1.000 p = 1.000 p = 1.000
REM
Gen 1 F = 0.885 F = 1.586 F = 12.069 F = 2.343 F = 4.829
p = 0.349 p = 0.211 p < 0.001*** p = 0.129 p = 0.030*
Time 7 F = 0.350 F = 0.083 F = 0.120 F = 0.245 F = 0.115
p = 0.928 p = 0.999 p = 0.997 p = 0.973 p = 0.997
Inter 7 F = 0.118 F = 0.134 F = 0.348 F = 0.401 F = 0.209
p = 0.997 p = 0.995 p = 0.930 p = 0.899 p = 0.983
“Genotype” and “time” were used as factors to examine the effects of genotype (Gen) and time (3 h intervals) on spectral power for each behavioural state (WT
n = 7, KI n = 7). The table displays the degree of freedom (Df), F values, and significance levels (p) for the factors and the genotype-time interactions (Inter) in the
analysis. * p <0.05. ** p <0.01. *** p <0.001
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showed in Fig. 6 and in Table 1. This further supports
that the effect of genotype on frequency bands is not
time-dependent. The difference found on time effect
between this analysis and the analysis done in Fig. 6 is
likely due the fact that by normalizing the power of fre-
quency band within each epoch to the total activity of
the targeted band in the entire recording is more sensi-
tive in revealing the time effect.
Discussion
In this study, we recorded EEG-EMG activity in the
Nlgn3R451C KI mice and their WT littermates to investi-
gate whether the Nlgn3 R451C mutation is involved in
sleep regulation. We found that both WT and
Nlgn3R451C mutant mice spent more time sleeping dur-
ing the light phase compared to the dark, consistent
with the typical time distribution of vigilance states in
Fig. 6 Altered power spectral profiles in Nlgn3R451C mutant mice. The power of the individual frequency band was normalized by expressing it as
% of the mean of total power (1-56 Hz for all epochs). The mean normalized power of each 3-h interval (of both days) is displayed over the 24-h
period. “Genotype” and “time” were used as factors to examine their effects on delta, theta, alpha, sigma, and beta powers in each behavioural
vigilance state (only data with significant genotype effect are displayed here). During wakefulness, Nlgn3R451C (KI) mice exhibited significantly
higher sigma (a) and beta (b) powers than WT mice (p <0.05). During NREM sleep, Nlgn3R451C mice showed suppressed delta (c), theta (d), and
alpha (e) powers than WT mice (p <0.05). During REM sleep, Nlgn3R451C mice exhibited significantly lower alpha (f) and higher beta (g) powers
than WT (p <0.05). No significant interactions between genotype and time were found (all p >0.05)
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nocturnal rodents [40]. Nlgn3R451C mutant mice were
also not different from their WT controls in the total
amount of time as well as the total number and dura-
tions of episodes for each sleep/wake state, suggesting
that Nlgn3R451C mutation alone may not be sufficient to
cause reduced sleep time or frequent waking observed in
patients with ASD [3, 4, 11]. However, Nlgn3R451C mu-
tant mice exhibited significantly altered EEG power
spectra profiles, suggesting that this mutation may con-
tribute to alterations in the quality of sleep/wake states.
During wakefulness, the Nlgn3R451C mice exhibited
increased sigma and beta spectral powers compared to
WT. The significance of these changes is unknown.
Delta power during NREM sleep was significantly
reduced in Nlgn3R451C mutant mice, which may reflect
heightened arousal and ‘lighter’ sleep in the mutants
[35, 45]. The mechanism for the reduced delta power
is unknown, but it may be related to altered GABA
inhibitory transmission. Delta oscillations are generated by
the thalamo-corticol network and are regulated by
GABAergic transmission [38, 46–49], and interestingly, a
reduction in E/I ratio in the somatosensory cortex was
reported in the Nlgn3R451C mutant mice due to increased
inhibitory synaptic transmission without changes in exci-
tatory transmission in this region [24, 30]. Consistent with
this finding, suppression of delta oscillations was also
observed following the administration of diazepam, a
GABA agonist [38, 50]. Theta oscillations, which are
predominantly generated by the hippocampal network
[40, 51, 52], were also reduced in Nlgn3R451C mutant mice
during NREM sleep. Previously, Nlgn3R451C mutants mice
were demonstrated to have increased excitatory gluta-
matergic synaptic transmission without alterations in
inhibitory GABAergic transmission in the hippocampus,
resulting in an augmented E/I ratio in this region [30].
Surprisingly, a reduction in E/I ratio via diazepam admin-
istration also reduced theta oscillations during NREM
sleep [38]. As diazepam increases GABAergic transmis-
sion, which is not affected in the Nlgn3R451C mutant
hippocampus [30], these data suggest that Nlgn3 may
regulate NREM sleep theta oscillations via mechanisms
independent of GABAergic signalling. Alpha oscillations,
which are believed to be generated by cortico-cortical and
thalamo-cortical networks [40], were reduced during both
NREM and REM sleep in Nlgn3R451C mutant mice. Alpha
oscillations are thought to reflect input from dorsal anter-
ior cingulate cortex, anterior insula, and thalamus that
relay sensory information to the cortex, signalling the
brain of external stimuli [43, 53]. Increased alpha power
during REM sleep therefore may reflect micro-arousal
during REM sleep and possibly contributing to REM
sleep instability [39, 43, 54]. Hence, the reduced alpha
power in Nlgn3R451C KI mice might indicate more
stable REM sleep in these mutants. Although the
significance of alpha power reduction for sleep/wake
regulation remains unclear, it is consistent with the
increased cortical GABAergic transmission as diazepam
also suppresses alpha oscillations [50]. In human, beta
oscillations (15-30 Hz) are reflective of cortical arousal
within sleep [37, 45]. Although, the changes in beta
power in patients with insomnia are variable during
REM sleep [45], several reports have demonstrated in-
creased beta power in REM sleep in patients with pri-
mary insomnia [37, 41, 55]. It is plausible the increased
beta oscillations during REM sleep may also suggest
poor sleep quality in Nlgn3R451C mice. The simultan-
eously reduced alpha power and increased beta power
may indicate the simultaneous activation of both
wake-promoting and sleep-promoting mechanisms in
Nlgn3R451C mice.
It is interesting to note that the alterations in spectral
powers in Nlgn3R451C mice are quite different from those
found in Nlgn1KO mice [31]. For example, Nlgn1KO
mice showed decreased high delta, theta, alpha powers
during wakefulness while showing a trend of increased
delta power during NREM, whereas Nlgn3R451C mutant
mice exhibited increased sigma and beta bands during
wakefulness and reduced delta, theta, and alpha powers
during NREM sleep. These results suggest that the role of
neuroligins in sleep/wake regulation is dependent on
specific members of the neuroligin gene family. Consistent
with this possibility, members of the neuroligin family
show different patterns of expression and modes of regu-
lation [21, 22]. However, it is possible that in Nlgn3R451C
mutant mice, there may be developmental compensations
that alter the expression of other proteins, including Nlgn
1, which could complicate the interpretation of the results.
It is also possible that members of the neuroligin family
cross-talk so that the deletion of one member affects the
functionality of the others. Further studies are needed to
elucidate whether and how these interactions and specifi-
city are achieved and their impact on sleep/wake states by
using acute manipulations and a combination of knockout
mice lacking one or more neuroligins. Lastly, we found a
trend of reduced NREM sleep in Nlgn3R451C mice (Fig. 3).
Future studies using higher number of mice may help
better elucidate the effect of Nlgn3R451C on NREM sleep.
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